Status:
RECRUITING
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Manchester University NHS Foundation Trust
Tayside Medical Science Centre
Conditions:
Chronic Pulmonary Aspergillosis
Eligibility:
All Genders
18+ years
Brief Summary
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients \>/= 18 years old and able to provide informed consent
- Patients with a diagnosis of chronic pulmonary aspergillosis
- To speak and understand English
- Able to provide informed consent
Exclusion
Key Trial Info
Start Date :
November 27 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 23 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06885905
Start Date
November 27 2024
End Date
April 23 2026
Last Update
March 20 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Ninewells Hospital & Medical School
Dundee, United Kingdom, DD1 9SY
2
Imperial College London
London, United Kingdom
3
Manchester NHS Foundation Trust
Manchester, United Kingdom